Authorship, funding, disclosures
Additional authors included co-lead author Lauren E. Milling, Priyamvada Prathima, Vivian Li, Ashlyn M. Lemmen, Ivy S.L. Streeter, Paul K.S. Heisig, Nicole M. Derosia, Elizabeth Riffo, Haonan Xu, Thao H. Nguyen, Aashiya Kolengaden, Samuel C. Markson, and John G. Doench.
This work was supported by the National Institutes of Health (National Institute of Allergy and Infectious Diseases grant U19AI133524 and National Cancer Institute award 1K99CA290077-01A1), a Cancer Research Institute Immuno-Informatics Postdoctoral Fellowship (CRI5009), and the American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists. LaFleur and Sharpe also received funding for this work from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ; the Blavatnik Biomedical Accelerator at Harvard University; the Quadrangle Fund for Advancing and Seeding Translational Research (Q-FASTR) at Harvard Medical School; and Calico Life Sciences LLC.
Sharpe has patents/pending royalties on the PD-1 pathway from Roche and Novartis.
LaFleur, Milling, Streeter, Lemmen, Hesing, Derosia, and Sharpe have a patent on methods for modulating STUB1 for the treatment of cancer. Sharpe is on advisory boards for Elpiscience, Monopteros Therapeutics, Corner Therapeutics, BioEntre, Alixia, GlaxoSmithKline, Janssen, Amgen, AltruBio, ImmVue, and MabQuest. Sharpe receives research funding from Calico Life Sciences LLC and Taiwan Bio. Doench consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo, and Pfizer. Doench consults for and has equity in Tango Therapeutics. Doench serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GlaxoSmithKline. Doench receives funding support from the Functional Genomics Consortium: AbbVie; Bristol Myers Squibb; Janssen; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ. Doench’s interests were reviewed and are managed by the Broad Institute in accordance with its conflict-of-interest policies.